65, P<0.001and parabolic minimum of 6 (Figure 5). That Is, 65% of the variance In the behavioral ratings could be explained by the clrcadlan misalignment component. Patients who became overly phase advanced on the PM melatonin and shifted across the sweet spot were more depressed than those who had shifted closer to PAD 6 (Figure

6). Figure 5. Post-treatment SIGH-SAD score as a function of PAD. The parabolic #BIBW2992 in vitro keyword# curve (minimum =6. 18) indicates that PAD accounts for 11% of the variance in SIGH-SAD scores [F (2, 65)=3.96] for all subjects and 19% for phase-delayed subjects [F (2,45)=5.19]. Absolute … Figure 6. Post-treatment SIGH-SAD score as a function of PAD in delayed subjects. (The parabolic Inhibitors,research,lifescience,medical curve and related statistics for the delayed subjects are provided in Figure 4). The linear correlation between PAD and SIGH-SAD score (diagonal hatched line) did not … In this figure (which also Includes prototypical patients treated with AM melatonin and placebo), we did not find a statistically significant linear correlation, as reported by the Terman research group with respect to the decrease in depression ratings change scores plotted against phase advances in the DLMO.22 Therefore, Inhibitors,research,lifescience,medical while there is some consistency between their study and ours,

there are some clear differences leading to differing treatment recommendations. Terman group claims the key to understanding the circadian mechanism of light lies in its ability to cause a phase advance; the greater the phase advance, the greater the antidepressant effect. This does not take into account the possibility that some patients

may do better with evening light so as to provide a corrective phase delay. Furthermore, the Terman group recommends Inhibitors,research,lifescience,medical that patients Inhibitors,research,lifescience,medical awaken earlier than usual in order to schedule light at an earlier circadian time. However, an earlier wake time would shorten PAD, and, according to our findings, would compromise light’s antidepressant effect in the prototypical phase-delayed patient. Moreover, we would predict that these prototypical patients would do less well if overly phase advanced by light scheduled too early; it had been known for some time that as long as the light was not scheduled too many hours before dawn, the earlier light exposure was scheduled relative to Isotretinoin the DLMO, the greater was its phase-advancing effect. In our study, we also compared SIGH-SAD change scores versus changes in PAD (Figure 7). This figure requires some explanation. If a subject had a pretreatment PAD of 4 and a post-treatment PAD of either 5 or 7, this would represent a change closer to PAD 6 of 1. If the same subject had a post-treatment PAD of 8, this would represent a change closer to PAD 6 of 0. If the same subject had a post-treament PAD of either 9 or 3, this would represent a change closer to PAD 6 of -1, that Is, the PAD Is f hour further away from PAD 6, after treatment than before treatment.